Also found in: Thesaurus, Medical, Encyclopedia, Wikipedia.
click for a larger image


n. pl. en·ta·ses (-sēz′)
A slight convexity or swelling, as in the shaft of a column, conventionally employed especially in classical architecture.

[Latin, from Greek, tension, from enteinein, to stretch tight : en-, intensive pref.; see en-2 + teinein, to stretch; see ten- in Indo-European roots.]


n, pl -ses (-siːz)
1. (Architecture) a slightly convex curve given to the shaft of a column, pier, or similar structure, to correct the illusion of concavity produced by a straight shaft
2. (Physiology) physiol Also called: entasia an involuntary or spasmodic muscular contraction
[C18: from Greek, from enteinein to stretch tight, from teinein to stretch]


(ˈɛn tə sɪs)

a slight convexity given to a column or tower to correct the optical illusion of concavity produced by straight sides.
[1745–55; < Greek, =enta- (variant s. of enteínein to stretch tight =en- en-2 + teínein to stretch) + -sis -sis]


the slight convexity or outward curve given to a tower or other tall, narrow structure.
See also: Architecture
ThesaurusAntonymsRelated WordsSynonymsLegend:
Noun1.entasis - a slight convexity in the shaft of a columnentasis - a slight convexity in the shaft of a column; compensates for the illusion of concavity that viewers experience when the sides are perfectly straight
pillar, column - (architecture) a tall vertical cylindrical structure standing upright and used to support a structure
convex shape, convexity - a shape that curves or bulges outward
References in periodicals archive ?
Wainwright initiated coverage on Entasis Therapeutics Holdings Inc (NASDAQ: ETTX) with a Buy rating.
"We continued to make steady progress across all our pipeline programs in the first half of 2019," commented Manos Perros, President and Chief Executive Officer of Entasis Therapeutics.
The study was funded by the National Institutes of Health and Entasis Therapeutics.
Hastings Joins Entasis Therapeutics Board of Directors
A 30-year biopharmaceutical industry veteran, White was most recently Chief Business Officer at Entasis Therapeutics, where he led commercial planning, business development, and fundraising.
He is currently working at Entasis Teknoloji as an energy efficiency expert.
In partnership with the NIAID, the company Entasis recently completed a phase II study of zoliflodacin, an oral agent in a novel class of topoisomerase inhibitors.
The CDC said data presented by the LSU researchers on ETX0914, developed by Entasis Therapeutics, indicated the experimental antibiotic is generally safe and effective.